{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:49:25Z","timestamp":1779396565187,"version":"3.53.1"},"reference-count":38,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>We undertook an analysis of the Canadian Agency for Drugs and Technologies in Health (CADTH)\u2019s health technology assessments (HTAs) of systemic therapies for solid tumour indications to determine if a mechanism to re-evaluate HTA decisions is needed based on the level of certainty supporting the original recommendation. To measure the certainty in the evidence, we analysed if: (1) overall survival (OS) was the primary endpoint in the pivotal trial, (2) median OS was available at the time of the recommendation, and (3) the expert review committee explicitly identified gaps in the evidence. There were 96 drugs approved by Health Canada that met our eligibility criteria between 1 January 2017 and 31 October 2021. Median OS was not estimable at the time of the recommendation in 57% of the positive recommendations, and the uncertainty in the magnitude of clinical benefit was identified by the expert review committee in 21% of the positive recommendations. There is uncertainty at the time of the HTA recommendation for many drugs, and thus a need to implement a process to re-evaluate drugs in Canada to allow patients timely access to promising therapies while ensuring long-term value of therapies to patients and the healthcare system.<\/jats:p>","DOI":"10.3390\/curroncol29030156","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T20:19:10Z","timestamp":1646943550000},"page":"1919-1931","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021"],"prefix":"10.3390","volume":"29","author":[{"given":"Sandeep","family":"Sehdev","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre and The University of Ottawa, Ottawa, ON K1N 6N5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-2369","authenticated-orcid":false,"given":"Alexandra","family":"Chambers","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Inc. Canada, Dorval, ON H9S 1A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.healthpol.2017.03.010","article-title":"HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey","volume":"123","author":"Balbino","year":"2019","journal-title":"Health Policy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jval.2013.10.008","article-title":"A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries","volume":"17","author":"Barnieh","year":"2014","journal-title":"Value Health"},{"key":"ref_3","unstructured":"Health Canada (2021, December 10). Guidance for Industry\u2014Priority Review of Drug Submissions, Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/priority-review\/drug-submissions.html."},{"key":"ref_4","unstructured":"Health Canada (2021, December 10). Guidance Document: Notice of Compliance with Conditions (NOC\/c), Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/notice-compliance-conditions.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"m4087","DOI":"10.1136\/bmj.m4087","article-title":"Mortality due to cancer treatment delay: Systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1634\/theoncologist.2019-0314","article-title":"Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada","volume":"25","author":"Gotfrit","year":"2019","journal-title":"Oncologist"},{"key":"ref_7","unstructured":"(2021, December 10). CADTH 2018\u20132021 Strategic Plan: Transforming How We Manage Health Technologies. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/corporate\/planning_documents\/CADTH_2018_2021_Strategic_Plan_Overview.pdf."},{"key":"ref_8","unstructured":"(2021, December 10). CanREValue about Us\u2014Canadian Centre for Applied Research in Cancer Control. Available online: https:\/\/cc-arcc.ca\/canrevalue-about\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PPO.0b013e3181bdc2e0","article-title":"Overall Survival: Still the Gold Standard: Why overall survival remains the definitive end point in cancer clinical trials","volume":"15","author":"Driscoll","year":"2009","journal-title":"Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrclinonc.2011.156","article-title":"The value of progression-free survival to patients with advanced-stage cancer","volume":"9","author":"Fallowfield","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/annonc\/mdv562","article-title":"Statistical controversies in clinical research: End points other than overall survival are vital for regulatory approval of anticancer agents","volume":"27","author":"Saad","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_12","unstructured":"Health Canada (2021, December 10). Drug and Health Product Submissions Under Review (SUR): New Drug Submissions Completed, Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drug-health-product-review-approval\/submissions-under-review\/new-drug-submissions-completed.html."},{"key":"ref_13","unstructured":"(2021, December 10). Reimbursement Review Reports. Available online: https:\/\/www.cadth.ca\/reimbursement-review-reports."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.18.00729","article-title":"Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score","volume":"37","author":"Cherny","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_16","unstructured":"European Society of Medical Oncology (2021, December 10). ESMO-Magnitude of Clinical Benefit Scale (MCBS) Scorecards. Available online: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-scorecards?filterType=agent."},{"key":"ref_17","unstructured":"(2021, December 10). pCODR Expert Review Committee Recommendation for Lenvatinib for RCC, 2019. Available online: https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/Reviews2019\/10140LenvatinibRCC_FnRec_approvedbyChair_Post_04Jan2019_final.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E1573","DOI":"10.1503\/cmaj.211617","article-title":"Outdated criteria for drug plan reimbursement obstruct evidence-based care","volume":"193","author":"Bayoumi","year":"2021","journal-title":"Can. Med. Assoc. J."},{"key":"ref_19","unstructured":"Department of Health and Social Care (2021, December 10). Extent and Causes of International Variations in Drug Usage, Available online: https:\/\/www.gov.uk\/government\/publications\/extent-and-causes-of-international-variations-in-drug-usage."},{"key":"ref_20","unstructured":"England NHS (2021, December 10). NHS England \u00bb Cancer Drugs Fund. Available online: https:\/\/www.england.nhs.uk\/cancer\/cdf\/."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pham, F.-V., Jacquet, E., Monard, A., Brunel, L., Blay, J.-Y., and Albin, N. (2022). Added therapeutic benefit regarding ESMO-MCBS and French health technology assessment of drugs granted early access program. Ann. Oncol., in press.","DOI":"10.1016\/j.annonc.2022.02.002"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.healthpol.2018.09.016","article-title":"Implementing managed entry agreements in practice: The Dutch reality check","volume":"123","author":"Makady","year":"2019","journal-title":"Health Policy"},{"key":"ref_23","unstructured":"Siviero, P.D. (2021, December 10). Managed Entry Agreements as a Way to Implement Outcomes of Assessment and Enable Patient Access to Innovation, Available online: https:\/\/www.aifa.gov.it\/sites\/default\/files\/03-23-2012_siviero_p__dia_copenaghen_2012_1_0.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jval.2020.04.1731","article-title":"PCN265 characterisation of managed access agreements under the nice cancer drugs fund","volume":"23","author":"Hall","year":"2020","journal-title":"Value Health"},{"key":"ref_26","unstructured":"(2021, December 10). Cancer Drugs Fund|Technology Appraisal Guidance|NICE Guidance|Our Programmes|What We Do|about|NICE. Available online: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/cancer-drugs-fund."},{"key":"ref_27","unstructured":"(2021, December 10). BC Cancer Registry. Available online: http:\/\/www.bccancer.bc.ca\/health-professionals\/professional-resources\/bc-cancer-registry."},{"key":"ref_28","unstructured":"Alberta Health Services (2021, December 10). Alberta Cancer Registry, Available online: https:\/\/www.albertahealthservices.ca\/cancer\/Page17367.aspx."},{"key":"ref_29","unstructured":"(2021, December 10). Evidence Building Program (EBP). Available online: https:\/\/www.cancercareontario.ca\/en\/Funding\/Evidence_Building_Program."},{"key":"ref_30","unstructured":"English Summary (2021, December 10). Tisagenlecleucel for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Available online: https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Rapports\/Therapies_cellulaires\/INESSS_Kymriah_LLA_EnglishSummary.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vreman, R.A., Bloem, L.T., Van Oirschot, S., Hoekman, J., Van Der Elst, M.E., Leufkens, H.G., Klungel, O.H., Goettsch, W.G., and Mantel-Teeuwisse, A.K. (2020). The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. Int. J. Health Policy Manag., in press.","DOI":"10.34172\/ijhpm.2020.198"},{"key":"ref_32","unstructured":"(2021, December 10). pCODR Expert Review Committee Recommendation for Venetoclax for CLL, 2018. Available online: https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/pcodr_venetoclax_venclexta_cll_fn_rec.pdf."},{"key":"ref_33","unstructured":"(2021, December 10). pCODR Expert Review Committee Recommendation for Nivolumab for cHL, 2018. Available online: https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/pcodr_nivolumab_opdivo_cHL_fn_rec.pdf."},{"key":"ref_34","unstructured":"(2021, December 10). pCODR Expert Review Committee Recommendation for Pembrolizumab for cHL, 2018. Available online: https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/pcodr_pembrolizumab_keytruda_chl_fn_rec.pdf."},{"key":"ref_35","unstructured":"(2021, December 10). pCODR Expert Review Committee Recommendation for Olaratumab for Sarcoma, 2018. Available online: https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/pcodr_olaratumab_lartruvo_sts_fn_rec.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0266462320000215","article-title":"The new definition of health technology assessment: A milestone in international collaboration","volume":"36","author":"Oortwijn","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_37","unstructured":"Office of the Commissioner (2021, December 10). Project Orbis, Available online: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-orbis."},{"key":"ref_38","unstructured":"Health Canada (2021, December 10). Access Consortium, Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/international-activities\/australia-canada-singapore-switzerland-consortium.html."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/3\/156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:34:41Z","timestamp":1760135681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/3\/156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["curroncol29030156"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29030156","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}